


SYNTHETIC APPROACHES TO THIENAMYCIN: CARBON-CARBON
BOND FORMATION AT C-4 OF AZETIDIN-2-ONES

Paul J. Reider^{*}, Richard Rayford^{*}, and Edward J. J. Grabowski

Merck Sharp & Dohme Research Laboratories
P.O. Box 2000
Rahway, New Jersey 07065


A mild and efficient method of β -lactam alkylation has been achieved using 4-acetoxy-2-azetidinone and a variety of silyl enol ethers.

The discovery of thienamycin¹ and analogous 1-carbapenem antibiotics derived from various strains of *Streptomyces* (e.g. Olivanic acid², PS-5³) has resulted in an intense interest in the synthesis of the novel carbapenem skeleton.



The formation of a carbon-carbon bond at the 4-position of an azetidin-2-one opens up a wide variety of synthetic pathways to the carbapenems. Although already demonstrated⁴, the known methods suffer from low yields, complex reaction conditions, and functional group limitations. We wish to report a novel conversion of the readily available⁵ 4-acetoxyazetidin-2-one (2) into 4-alkylazetidin-2-ones containing useful functionality. This carbon-carbon bond formation occurs under mild conditions, in good yield, and appears to be general.

The Lewis acid catalyzed alkylation of ketones as their silyl enol ethers⁶ has been well demonstrated⁷. Reetz has recently shown that allylacetates are excellent electrophiles in these reactions using mild Lewis acids⁸. Karady *et. al.* have demonstrated the AgBF₄ mediated reaction of silyl enol ethers with 1-(*t*-butyldimethylsilyl)-4-chloroazetidin-2-ones in a new synthesis of thienamycin from penicillin⁹. In a logical extension of these observations we wish to report that the use of 4-acetoxyazetidin-2-one (2) as the alkylating agent has resulted in the synthesis of a variety of carbapenem precursors (Equation I).



A representative group of substrates successfully alkylated is shown in Table I.

Table I

<u>Entry</u>	<u>Silyl enol ether</u>	<u>Catalyst</u>	<u>Product^d</u>	<u>m.p.</u>	<u>Yield</u>
A)		ZnI ₂		138-140°C	83%
B)		ZnI ₂		-	83%
C)		ZnCl ₂		63-67°C	53%
D)		ZnCl ₂		100-101°C	54%

Notes: a) Ref. 4c
 b) Ref. 4e
 c) Ref. 10
 d) all products had physical and spectral properties fully in accord with known or expected values
 e) product 4 was isolated as a solid mixture of diastereomers - HPLC indicated 1:1 ratio

A typical experimental procedure is as follows:

A suspension of fused zinc iodide (160 mg, 0.5 mmol) in dichloromethane (3 mL) was treated at room temperature with 4-acetoxiazetidin-2-one (129 mg, 1.0 mmol) and the trimethylsilyl enol ether of acetophenone (384 mg, 2.0 mmol). After 2h, assay by TLC (SiO_2 , 1:1 toluene:ethyl acetate, $R_f = 0.15$) and HPLC (Dupont Zorbax ODS - C_{18} , 25 cm, elution with 65% H_2O : 35% CH_3CN with 0.1% H_3PO_4 at 1 mL/min, $R_t = 5.16$ min) indicated completion of the reaction. The reaction mixture was diluted with ethyl acetate (50 mL) washed with saturated NaHCO_3 (50 mL), brine (50 mL), and dried over MgSO_4 . Removal of the solvent gave the 4-Phenylcarbonylmethyl-2-azetidinone (**3**) as a solid contaminated with acetophenone. Recrystallization from benzene gave crystalline product (m.p. 138-140°C, lit^{4c} m.p. 141-143°C) in 83% yield (157 mg).

It should be noted that, as in the case described by Karady, use of the silyl enol ether of benzyl diazoacetate⁹ (see Table I, entry D) allows the direct introduction of a four carbon synthon^{4b} onto a β -lactam. This diazoketoester **6** has been cyclized¹⁰ with rhodium (II) acetate to give the 1-carbapenem structure in near quantitative yield.

The incorporation of this chemistry into an efficient asymmetric synthesis of thienamycin will be reported shortly.

Acknowledgements

We would like to thank Dr. Sandor Karady and Mr. Joseph Amato of these laboratories for many helpful discussions. We are grateful for the many intermediates and procedures they supplied.

References

1. Albers-Schönberg, G., Arison, B. H., Hensens, O. D., Hirshfield, J., Hoogsteen, K., Kaczka, E. A., Rhodes, R. E., Kahan, J. S., Kahan, F. M., Ratcliffe, R. W., Walton, E., Ruswinkle, L. J., Morin, R. B., and Christensen, B. G., J. Am. Chem. Soc., 1978, **100**, 6491.
2. a) Brown, A. G., Corbett, D. F., Eglington, A. J., and Howarth, T. T., J. Chem. Soc. Chem. Comm., 1977, 523.
 b) Maeda, K., Takahashi, S., Sezaki, M., Iinuma, K., Naganawa, H., Kondo, S., Ohno, M., and Umezawa, H., J. Antibiotics, 1977, **30**, 770.
 c) Brown, A. G., Corbett, D. F., Eglington, A. J., and Howarth, T. T., J. Antibiotics, 1979, **32**, 961.

3. Okamura, K., Hirata, S., Okumura, Y., Fukagawa, Y., Shimauchi, Y., Kuono, K., Ishikura, T., and Lein, J., J. Antibiotics, 1978, 31, 480.
4. a) Onoue, H., Narisada, M., Uyeo, S., Matsumura, H., Okada, K., Yano, T., and Nagata, W., Tetrahedron Lett., 1979, 3867.
b) Kametani, T., Honda, T., Nakayama, A., Fukumoto, K., Heterocycles, 1980, 14, 1967.
c) Oida, S., Yoshida, A., and Ohki, E., Chem. Pharm. Bull., 1980, 28, 3494.
d) Kobayashi, T., Ishida, N., and Hiraoka, T., J. Chem. Soc. Chem. Comm., 1980, 736.
e) Kametani, T., Honda, T., Sasaki, J., Terasawa, H., Nakayama, Y., and Fukumoto, K., Heterocycles, 1980, 14, 575.
5. Clauss, K., Grimm, D., and Prossel, G., Liebig's Ann. Chem., 1974, 477.
6. House, H. O., Czuba, L. J., Gall, M., Olmstead, H., J. Org. Chem., 1969, 34, 2324.
7. a) Rasmussen, J. K., Synthesis, 1977, 91.
b) Chan, T. H., Paterson, I., and Pinsonnault, J., Tetrahedron Lett., 1977, 4183.
c) Paterson, I., Tetrahedron Lett., 1979, 1519.
d) Reetz, M. T. and Maier, W. F., Angew. Chem. Int'l. Ed. Engl., 1978, 17, 48.
e) Reetz, M. T. and Schwellnus, K., Tetrahedron Lett., 1978, 1455.
f) Mukaiyama, T., Angew. Chem. Int'l. Ed. Engl., 1977, 16, 817.
8. Reetz, M. T., Hüttenhain, S., and Hübner, F., Syn. Comm., 1981, 11, 217.
9. Karady, S., Amato, J. S., Reamer, R. A., and Weinstock, L. M., J. Am. Chem. Soc., in press.
10. Ratcliffe, R. W., Salzmann, T. N., and Christensen, B. G., Tetrahedron Lett., 1980, 21, 31.

(Received in USA 30 October 1981)

*Merck Sharp and Dohme Research Laboratories Summer Intern